Dermelix is a biopharma startup, specializing in orphan genetic disorders.
What’s that mean?
It means they develop drugs to treat really rare diseases. And that’s just plain cool.
Because the folks at Dermelix care more easing suffering than kowtowing to investors looking to make a quick billion.
The Changeup Stays the Same
Now, being emotionally connected to Dermelix’s mission wasn’t hard. What was tricky was halfway through the project, the company changed CEOs.
What would normally throw any design project off-track (or just plain kill it), turned out to be a minor hiccup. Dermelix’s core values shone just as brightly in the new leadership because they held the same core value – of putting people first.
So, even in the change-rich environment of biopharma startups, the more things change, the more they stay the same. 🙂